Literature DB >> 31859355

Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway.

Aksel Thuv Nilsen1, Christine Karlsen1, Gunnstein Bakland1,2, Richard Watts3,4, Raashid Luqmani5, Wenche Koldingsnes1.   

Abstract

OBJECTIVE: ANCA-associated vasculitides (AAV) have increased in prevalence since the 1980s. We aimed to investigate the incidence and prevalence of AAV during a 15-year period from 1999 to 2013 in Northern Norway, looking for variations during this period.
METHODS: Patient records were retrieved from The Northern Norwegian Vasculitis Registry; in addition we searched all regional hospital databases. Patients diagnosed with AAV from 1999 through to 2013 were included. For prevalence data, patients residing in the area, but with AAV diagnosis prior to 1999, were also included. The diagnosis of AAV was based on the European Medicines Agency algorithm.
RESULTS: We identified 140 cases; 88 were classified as granulomatosis with polyangiitis (GPA), 37 as microscopic polyangiitis (MPA) and 15 as eosinophilic granulomatosis with polyangiitis (EGPA). Adult (age ≥15 years) annual incidence rates per million were as follows: for GPA 15.6 (95% CI: 12.5, 19.2), MPA 6.5 (95% CI: 4.6, 9.0), EGPA 2.7 (95% CI: 1.5, 4.5) and overall AAV 24.7 (95% CI: 20.8, 29.2). Incidences of MPA and overall AAV showed an increasing trend (P < 0.05). Adult point prevalence rates per million in 2013 were 261 (95% CI: 213, 316) for GPA, 58.2 (95% CI: 36.9, 87.3) for MPA, 32.9 (95% CI: 17.5, 56.3) for EGPA and 351 (95% CI: 296, 416) for overall AAV.
CONCLUSION: The incidence rate of GPA and the prevalence rates of GPA and EGPA are currently the highest reported. MPA increased significantly from a prior low incidence. The overall AAV annual incidence and prevalence are still increasing.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ANCA-associated vasculitis; eosinophilic granulomatosis with polyangiitis; epidemiology; granulomatosis with polyangiitis; incidence; microscopic polyangiitis; prevalence

Year:  2020        PMID: 31859355     DOI: 10.1093/rheumatology/kez597

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

1.  Systematic Review and Metaanalysis of Worldwide Incidence and Prevalence of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis.

Authors:  Rocío Redondo-Rodriguez; Natalia Mena-Vázquez; Alba María Cabezas-Lucena; Sara Manrique-Arija; Arkaitz Mucientes; Antonio Fernández-Nebro
Journal:  J Clin Med       Date:  2022-05-04       Impact factor: 4.964

2.  Increased incidence and improved prognosis of glomerulonephritis: a national 30-year study.

Authors:  James G Heaf; Søren S Sørensen; Alastair Hansen
Journal:  Clin Kidney J       Date:  2020-11-03

3.  Granulomatosis with polyangiitis and cardio vascular co-morbidity in Denmark. A registry-based study of 21 years of follow-up.

Authors:  Helle Laustrup; Anne Voss; Peter Enemark Lund
Journal:  J Transl Autoimmun       Date:  2021-11-19

Review 4.  Global epidemiology of vasculitis.

Authors:  Richard A Watts; Gulen Hatemi; Jane C Burns; Aladdin J Mohammad
Journal:  Nat Rev Rheumatol       Date:  2021-12-01       Impact factor: 20.543

5.  Thirty years of experience with anti-neutrophil cytoplasmic antibody glomerulonephritis in Charles Nicolle Hospital-Tunisia: a retrospective cohort study.

Authors:  Meriam Hajji; Samia Barbouch; Rim Goucha; Fethi Ben Hamida; Imen Gorsane; Ezzeddine Abderrahim
Journal:  Pan Afr Med J       Date:  2022-06-01

Review 6.  Environmental factors influencing the risk of ANCA-associated vasculitis.

Authors:  Wen-Man Zhao; Zhi-Juan Wang; Rui Shi; Yu-Yu Zhu; Sen Zhang; Rui-Feng Wang; De-Guang Wang
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

Review 7.  Neutrophils in ANCA-associated vasculitis: Mechanisms and implications for management.

Authors:  Shangqing Ge; Xingyu Zhu; Qinyao Xu; Junyan Wang; Cheng An; Ying Hu; Fan Yang; Xinyi Wang; Yipin Yang; Shuwen Chen; Ruimin Jin; Haiyan Li; Xinchen Peng; Yue Liu; Junnan Xu; Minhui Zhu; Zongwen Shuai
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.